Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
FGX
Faircourt Gold Income
C$2.60
+3.6%
C$2.60
C$2.32
C$3.58
C$7.21MN/A5,795 shs2,500 shs
USG Co. stock logo
USG
USG
$27.47
-1.0%
$33.42
$39.73
$43.50
$3.85B0.671.77 million shs433 shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%+1.80%
FGX
Faircourt Gold Income
0.00%0.00%0.00%0.00%0.00%
USG Co. stock logo
USG
USG
-1.23%+1.39%+0.86%+471.04%+471.04%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
FGX
Faircourt Gold Income
N/AN/AN/AN/AN/AN/AN/AN/A
USG Co. stock logo
USG
USG
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/A
FGX
Faircourt Gold Income
N/AN/AN/AN/A
USG Co. stock logo
USG
USG
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$15K124,613.93N/AN/A$3.09 per share4.77
FGX
Faircourt Gold Income
C$1.67M4.33C$4.10 per share0.63C$3.59 per share0.72
USG Co. stock logo
USG
USG
$3.34B1.15$1.66 per share16.51$13.73 per share2.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BELLUS Health Inc. stock logo
BLU
BELLUS Health
-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/A
FGX
Faircourt Gold Income
N/AC$0.2112.56N/AN/AN/AN/AN/A
USG Co. stock logo
USG
USG
$196M$1.5118.1921.13N/A5.88%11.65%5.67%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/A
FGX
Faircourt Gold Income
C$0.2911.08%N/A139.13%N/A
USG Co. stock logo
USG
USG
N/AN/AN/AN/AN/A

Latest FGX, BLU, KRM, FKE, and USG Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/18/2024
USG Co. stock logo
USG
USG
Quarterly$0.16902.61%3/19/20243/20/20243/22/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/A
33.42
33.42
FGX
Faircourt Gold Income
11.86
7.88
7.88
USG Co. stock logo
USG
USG
0.56
2.31
1.62

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BELLUS Health Inc. stock logo
BLU
BELLUS Health
90.37%
FGX
Faircourt Gold Income
N/A
USG Co. stock logo
USG
USG
80.74%

Insider Ownership

CompanyInsider Ownership
BELLUS Health Inc. stock logo
BLU
BELLUS Health
24.17%
FGX
Faircourt Gold Income
N/A
USG Co. stock logo
USG
USG
0.66%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BELLUS Health Inc. stock logo
BLU
BELLUS Health
74126.81 million96.16 millionNot Optionable
FGX
Faircourt Gold Income
N/A2.77 millionN/ANot Optionable
USG Co. stock logo
USG
USG
7,300140.10 millionN/AOptionable

FGX, BLU, KRM, FKE, and USG Headlines

Recent News About These Companies

USG Report – Goodbye from USG
Newswatch 12 Today
10pm Sunday Newscast
Arsenal chiefs to oversee departure of ten senior players
Graduating USG officials reflect on their incumbency

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BELLUS Health logo

BELLUS Health

NASDAQ:BLU
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Faircourt Gold Income

TSE:FGX
Faircourt Gold Income Corp. is a closed-ended equity mutual fund launched and managed by Faircourt Asset Management Inc. It invests in the public equity markets of Canada. The fund seeks to invest in stocks of companies operating in the precious metals sector, with an emphasis on companies involved in gold mining and exploration. It primarily invests in stocks of senior and intermediate gold producers that are part of the S&P/TSX Global Gold Index. The fund benchmarks the performance of its portfolio against S&P/TSX Global Gold Index. Faircourt Gold Income Corp. was formed on November 16, 2007 and is domiciled in Canada.
USG logo

USG

NYSE:USG
USG Corporation, through its subsidiaries, manufactures and sells building materials worldwide. The company's Gypsum division manufactures and markets gypsum and related products to construct walls and ceilings of residential, nonresidential, and institutional buildings; and agricultural and industrial customers. This segment offers gypsum wallboards and compound portfolios, as well as corner beads, joint tapes, and plasters under the USG Sheetrock brand; glass mat sheathing portfolios under the Securock brand; construction plaster products under the Red Top, Imperial, Diamond, and Supremo brands; and lightweight gypsum panels under the USG Sheetrock brand, as well as ultralight panels, USG Sheetrock brand ecosmart panels, and industrial gypsum. Its Performance Materials division manufactures and markets products for interior and exterior building applications of residential and nonresidential buildings, as well as industrial applications. This segment provides cement boards, backer boards, shower systems, performance floorings, air barrier systems, roof board portfolios, and structural panels under the USG Durock, Fiberock, Levelrock, Securock, ExoAir, Securock, and USG brands. The company's Ceilings division manufactures and markets ceiling tiles under the Radar, Eclipse, Mars, and Halcyon brands; ceiling grids under the Donn, DX, Fineline, Centricitee, and Identitee DXI brands; specialty ceilings under the Curvatura, Compasso, Radians, Illusions, Multiples, Runways, Barz, Planx, Mirra, Corniche, Wallforms, and Parti brands; and acoustical drywall ceilings under the Ensemble brand. Its USG Boral Building Products division manufactures, distributes, and sells building products, mines raw gypsum, and sells natural and synthetic gypsum under the USG Boral Sheetrock, USG Boral NextGen, Elephant, Jayaboard, Durock, and Donn DX brands. The company was founded in 1902 and is headquartered in Chicago, Illinois.